77 Ill. Adm. Code 661.310
Biotinidase Deficiency
Section 661.310Â Biotinidase Deficiency
a)Â Â Â Â Â Â Â Â Interpretation
of Results. Although the majority of infants affected by biotinidase
deficiency will be identified by this screening, due to genetic variabilities
and variations in health status, specimen quality, and timing of specimen
collection, not all infants affected by the disorder may be identified. As
with any laboratory test, false positive and false negative results are
possible. Newborn screening test results are insufficient information on which
to base diagnosis or treatment.
1)Â Â Â Â Â Â Â Â Laboratory
tests for biotinidase deficiency are designed to detect a deficiency of the
biotinidase enzyme. Normal test results indicate the presence of the enzyme.Â
Test results are abnormal when the presence of the enzyme is not detected.
2)Â Â Â Â Â Â Â Â When
the determination of the enzyme is deemed abnormal, the Department will
recommend a repeat newborn blood spot screening test or referral of the newborn
to a designated medical specialist for a quantitative determination of the
biotinidase enzyme and further diagnostic studies.
b)Â Â Â Â Â Â Â Â Designation
of Medical Specialist. In addition to the minimum qualifications set out in
Section 661.230, medical specialists designated by the Department to follow-up
on a screen positive for biotinidase deficiency shall possess certification by
the American Board of Medical Genetics and Genomics in Clinical Biochemical
Genetics, Medical Biochemical Genetics or certification by the American Board
of Medical Genetics and Genomics in Clinical Genetics with at least one year of
experience post-training in the diagnosis and treatment of biotinidase
deficiency and inborn errors of metabolism. Medical specialists should have
the capacity to provide a multidisciplinary approach to care, including the
availability on site of specially trained metabolic dietitians.
c)Â Â Â Â Â Â Â Â Diagnosis
and Treatment. Medical management by a designated medical specialist is highly
recommended. Therapy with pharmacological doses of biotin is required.Â
Long-term follow-up of children with biotinidase deficiency is necessary to
ensure proper growth and development.